Genetic variants in the VEGF pathway as prognostic factors in stages II and III colon cancer

[1]  E. Scarpi,et al.  Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy , 2017, International journal of molecular sciences.

[2]  D. Sargent,et al.  Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers: A Secondary Analysis of 2 Randomized Clinical Trials , 2017, JAMA oncology.

[3]  S. Kopetz,et al.  Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  M. Baiget,et al.  KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer , 2017, Clinical and Translational Oncology.

[5]  Debashis Sahoo,et al.  CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. , 2016, The New England journal of medicine.

[6]  V. Gouilleux-Gruart,et al.  Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab. , 2015, Pharmacogenomics.

[7]  D. Sargent,et al.  Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance) , 2015, Clinical Cancer Research.

[8]  K. Owzar,et al.  Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I–III Non–Small-Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  X. Fang,et al.  Different treatment strategies and molecular features between right-sided and left-sided colon cancers. , 2015, World journal of gastroenterology.

[10]  R. Salazar,et al.  Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Baiget,et al.  Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy , 2015, The Pharmacogenomics Journal.

[12]  T. Mok,et al.  Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer. , 2014, Lung cancer.

[13]  Seon-Young Kim,et al.  Single-Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Pathway and Outcomes of Patients Treated with First-Line Cytotoxic Chemotherapy Combined with Bevacizumab for Advanced Colorectal Cancer , 2014, Oncology.

[14]  A. Jemal,et al.  Colorectal cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[15]  A. Di Rienzo,et al.  Discovery and Functional Assessment of Gene Variants in the Vascular Endothelial Growth Factor Pathway , 2014, Human mutation.

[16]  D. Sargent,et al.  Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Baiget,et al.  The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients , 2013, Pharmacogenetics and genomics.

[18]  H. Lenz,et al.  Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer , 2012, The Pharmacogenomics Journal.

[19]  J. Lindebjerg,et al.  Prognostic importance of VEGF-A haplotype combinations in a stage II colon cancer population. , 2012, Pharmacogenomics.

[20]  Hushan Yang,et al.  Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer , 2012, Cancer science.

[21]  H. Lenz,et al.  Cancer Dormancy: A Model of Early Dissemination and Late Cancer Recurrence , 2011, Clinical Cancer Research.

[22]  H. Lenz,et al.  Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer , 2011, Clinical Cancer Research.

[23]  D. Kerr,et al.  Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Russ B. Altman,et al.  Vascular endothelial growth factor pathway. , 2010, Pharmacogenetics and genomics.

[25]  M. Gazouli,et al.  Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival , 2009, Molecular carcinogenesis.

[26]  H. Lenz,et al.  VEGF and VEGFR1 gene expression levels and tumor recurrence in adjuvant colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Alexandra Pohl,et al.  Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer , 2009, Pharmacogenetics and genomics.

[28]  S. Groshen,et al.  Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  L. Claesson‐Welsh,et al.  VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.

[30]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[32]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.